OBJECTIVES: This study evaluated the safety of coronary reactivity testing (CRT) in symptomatic women with evidence of myocardial ischemia and no obstructive coronary artery disease (CAD). BACKGROUND: Microvascular coronary dysfunction (MCD) in women with no obstructive CAD portends an adverse prognosis of a 2.5% annual major adverse cardiovascular event (MACE) rate. The diagnosis of MCD is established by invasive CRT, yet the risk of CRT is unknown. METHODS: The authors evaluated 293 symptomatic women with ischemia and no obstructive CAD, who underwent CRT at 3 experienced centers. Microvascular function was assessed using a Doppler wire and injections of adenosine, acetylcholine, and nitroglycerin into the left coronary artery. CRT-related serious adverse events (SAEs), adverse events (AEs), and follow-up MACE (death, nonfatal myocardial infarction [MI], nonfatal stroke, or hospitalization for heart failure) were recorded. RESULTS: CRT-SAEs occurred in 2 women (0.7%) during the procedure: 1 had coronary artery dissection, and 1 developed MI associated with coronary spasm. CRT-AEs occurred in 2 women (0.7%) and included 1 transient air microembolism and 1 deep venous thrombosis. There was no CRT-related mortality. In the mean follow-up period of 5.4 years, the MACE rate was 8.2%, including 5 deaths (1.7%), 8 nonfatal MIs (2.7%), 8 nonfatal strokes (2.7%), and 11 hospitalizations for heart failure (3.8%). CONCLUSIONS: In women undergoing CRT for suspected MCD, contemporary testing carries a relatively low risk compared with the MACE rate in these women. These results support the use of CRT by experienced operators for establishing definitive diagnosis and assessing prognosis in this at-risk population. (Women's Ischemia Syndrome Evaluation [WISE]; NCT00832702).
OBJECTIVES: This study evaluated the safety of coronary reactivity testing (CRT) in symptomatic women with evidence of myocardial ischemia and no obstructive coronary artery disease (CAD). BACKGROUND:Microvascular coronary dysfunction (MCD) in women with no obstructive CAD portends an adverse prognosis of a 2.5% annual major adverse cardiovascular event (MACE) rate. The diagnosis of MCD is established by invasive CRT, yet the risk of CRT is unknown. METHODS: The authors evaluated 293 symptomatic women with ischemia and no obstructive CAD, who underwent CRT at 3 experienced centers. Microvascular function was assessed using a Doppler wire and injections of adenosine, acetylcholine, and nitroglycerin into the left coronary artery. CRT-related serious adverse events (SAEs), adverse events (AEs), and follow-up MACE (death, nonfatal myocardial infarction [MI], nonfatal stroke, or hospitalization for heart failure) were recorded. RESULTS: CRT-SAEs occurred in 2 women (0.7%) during the procedure: 1 had coronary artery dissection, and 1 developed MI associated with coronary spasm. CRT-AEs occurred in 2 women (0.7%) and included 1 transient air microembolism and 1 deep venous thrombosis. There was no CRT-related mortality. In the mean follow-up period of 5.4 years, the MACE rate was 8.2%, including 5 deaths (1.7%), 8 nonfatal MIs (2.7%), 8 nonfatal strokes (2.7%), and 11 hospitalizations for heart failure (3.8%). CONCLUSIONS: In women undergoing CRT for suspected MCD, contemporary testing carries a relatively low risk compared with the MACE rate in these women. These results support the use of CRT by experienced operators for establishing definitive diagnosis and assessing prognosis in this at-risk population. (Women's Ischemia Syndrome Evaluation [WISE]; NCT00832702).
Authors: Johannes Rieber; Philip Jung; Thomas M Schiele; Andreas Koenig; Isabelle Erhard; Tobias Segmiller; Silke Ebel; Karl Theisen; Uwe Siebert; Volker Klauss Journal: Z Kardiol Date: 2002
Authors: S E Reis; R Holubkov; A J Conrad Smith; S F Kelsey; B L Sharaf; N Reichek; W J Rogers; C N Merz; G Sopko; C J Pepine Journal: Am Heart J Date: 2001-05 Impact factor: 4.749
Authors: Bernard De Bruyne; Nico H J Pijls; Emanuele Barbato; Jozef Bartunek; Jan-Willem Bech; William Wijns; Guy R Heyndrickx Journal: Circulation Date: 2003-03-31 Impact factor: 29.690
Authors: A Jeremias; R J Whitbourn; S D Filardo; P J Fitzgerald; D J Cohen; E M Tuzcu; W D Anderson; A A Abizaid; G S Mintz; A C Yeung; M J Kern; P G Yock Journal: Am Heart J Date: 2000-10 Impact factor: 4.749
Authors: Julian P J Halcox; William H Schenke; Gloria Zalos; Rita Mincemoyer; Abhiram Prasad; Myron A Waclawiw; Khaled R A Nour; Arshed A Quyyumi Journal: Circulation Date: 2002-08-06 Impact factor: 29.690
Authors: Mark A Marinescu; Adrián I Löffler; Michelle Ouellette; Lavone Smith; Christopher M Kramer; Jamieson M Bourque Journal: JACC Cardiovasc Imaging Date: 2015-02
Authors: Jaime L Shaw; Michael D Nelson; Janet Wei; Manish Motwani; Sofy Landes; Puja K Mehta; Louise E J Thomson; Daniel S Berman; Debiao Li; C Noel Bairey Merz; Behzad Sharif Journal: Int J Cardiol Date: 2018-06-22 Impact factor: 4.164
Authors: Hernán Mejía-Rentería; Nina van der Hoeven; Tim P van de Hoef; Julius Heemelaar; Nicola Ryan; Amir Lerman; Niels van Royen; Javier Escaned Journal: Int J Cardiovasc Imaging Date: 2017-05-13 Impact factor: 2.357
Authors: Janet Wei; Michael D Nelson; Edward W Szczepaniak; Laura Smith; Puja K Mehta; Louise E J Thomson; Daniel S Berman; Debiao Li; C Noel Bairey Merz; Lidia S Szczepaniak Journal: Am J Physiol Heart Circ Physiol Date: 2015-10-30 Impact factor: 4.733
Authors: Arnav Kumar; Olivia Y Hung; Marina Piccinelli; Parham Eshtehardi; Michel T Corban; David Sternheim; Boyi Yang; Adrien Lefieux; David S Molony; Elizabeth W Thompson; Wenjie Zeng; Yasir Bouchi; Sonu Gupta; Hossein Hosseini; Mohamad Raad; Yi-An Ko; Chang Liu; Michael C McDaniel; Bill D Gogas; John S Douglas; Arshed A Quyyumi; Don P Giddens; Alessandro Veneziani; Habib Samady Journal: JACC Cardiovasc Interv Date: 2018-09-26 Impact factor: 11.195
Authors: Megha Agarwal; Chrisandra Shufelt; Puja K Mehta; Edward Gill; Daniel S Berman; Debiao Li; Behzad Sharif; Ning Li; C Noel Bairey Merz; Louise E J Thomson Journal: Cardiovasc Diagn Ther Date: 2013-09